New drug XMT-1660 enters human trials for Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase study tests a new drug called XMT-1660 in people with advanced solid tumors, including triple-negative breast, ovarian, and endometrial cancers. The main goals are to find a safe dose and check for side effects. About 319 participants will receive the drug, and r…
Phase: PHASE1 • Sponsor: Mersana Therapeutics • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC